Quantifying Variation in Home Spirometry in People with Cystic Fibrosis During Baseline Health, and Associations with Clinical Outcomes

Overview

Journal J Cyst Fibros

Publisher Elsevier

Specialty Pulmonary Medicine

Date 2023 May 27

PMID 37244842

Authors

Christina S Thornton

Amalia S Magaret

Lisa A Carmody

Linda M Kalikin

Richard H Simon

John J LiPuma

Lindsay J Caverly

Affiliations

Soon will be listed here.

Abstract

Background: Home spirometry is increasingly used to monitor lung function in people with cystic fibrosis (pwCF). Although decreases in lung function in the setting of increased respiratory symptoms are consistent with a pulmonary exacerbation (PEx), the interpretation of home spirometry during asymptomatic periods of baseline health is unclear. The aims of this study were to determine the variation in home spirometry in pwCF during asymptomatic periods of baseline health and to identify associations between this variation and PEx.

Methods: Near-daily home spirometry measurements were obtained from a cohort of pwCF enrolled in a long-term study of the airway microbiome. Associations between the degree of variation in home spirometry and the time to next PEx were evaluated.

Results: Thirteen subjects (mean age of 29 years and mean percent predicted forced expiratory volume in one second [ppFEV] of 60) provided a median of 204 spirometry readings taken during 40 periods of baseline health. The mean week-to-week within-subject level of variation in ppFEV was 15.2 ± 6.2%. The degree of variation in ppFEV during baseline health was not associated with time to PEx.

Conclusions: Variation in ppFEV measured with near-daily home spirometry in pwCF during periods of baseline health exceeded the variation in ppFEV expected in clinic spirometry (based on ATS guidelines). The degree of variation in ppFEV during baseline health was not associated with time to PEx. These data are relevant for guiding interpretation of home spirometry.

Citing Articles

Baseline-dependent improvement in CF studies, plausibility of bias.

Graham E, Heltshe S, Magaret A Contemp Clin Trials Commun. 2024; 42:101378.

PMID: 39678155 PMC: 11639362. DOI: 10.1016/j.conctc.2024.101378.

Accuracy, Reproducibility, and Responsiveness to Treatment of Home Spirometry in Cystic Fibrosis: Multicenter, Retrospective, Observational Study.

Oppelaar M, van Helvoort H, Bannier M, Reijers M, van der Vaart H, van der Meer R J Med Internet Res. 2024; 26:e60892.

PMID: 39626236 PMC: 11653036. DOI: 10.2196/60892.

Impact of day-to-day variation in FEV1 on measures of change: A conceptual description.

Magaret A, Graham E, Caverly L, Cromwell E, Paynter A, Rosenfeld M J Cyst Fibros. 2024; 23(5):943-946.

PMID: 39147620 PMC: 11410506. DOI: 10.1016/j.jcf.2024.07.005.

Cystic fibrosis year in review 2023.

Swetland D, Savant A Pediatr Pulmonol. 2024; 59(12):3106-3116.

PMID: 39056532 PMC: 11601032. DOI: 10.1002/ppul.27190.

Microbial community organization designates distinct pulmonary exacerbation types and predicts treatment outcome in cystic fibrosis.

Widder S, Carmody L, Opron K, Kalikin L, Caverly L, LiPuma J Nat Commun. 2024; 15(1):4889.

PMID: 38849369 PMC: 11161516. DOI: 10.1038/s41467-024-49150-y.

References

Goss C, Burns J . Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax. 2007; 62(4):360-7. PMC: 2092469. DOI: 10.1136/thx.2006.060889. View

Compton M, List R, Starheim E, Somerville L, Williamson L, Murray R . Home spirometry utilisation in telemedicine clinic for cystic fibrosis care during COVID-19 pandemic: a quality improvement process. BMJ Open Qual. 2021; 10(3). PMC: 8390143. DOI: 10.1136/bmjoq-2021-001529. View

Lechtzin N, Mayer-Hamblett N, West N, Allgood S, Wilhelm E, Khan U . Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results. Am J Respir Crit Care Med. 2017; 196(9):1144-1151. PMC: 5694835. DOI: 10.1164/rccm.201610-2172OC. View

Rondeau V, Commenges D, Joly P . Maximum penalized likelihood estimation in a gamma-frailty model. Lifetime Data Anal. 2003; 9(2):139-53. PMC: 1961627. DOI: 10.1023/a:1022978802021. View

Pellegrino R, Viegi G, Brusasco V, Crapo R, Burgos F, Casaburi R . Interpretative strategies for lung function tests. Eur Respir J. 2005; 26(5):948-68. DOI: 10.1183/09031936.05.00035205. View

Cooper P, Robertson C, Hudson I, Phelan P . Variability of pulmonary function tests in cystic fibrosis. Pediatr Pulmonol. 1990; 8(1):16-22. DOI: 10.1002/ppul.1950080107. View

Miller M, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A . Standardisation of spirometry. Eur Respir J. 2005; 26(2):319-38. DOI: 10.1183/09031936.05.00034805. View

Caverly L, Caverly T, Kalikin L, Foster B, Simon R, LiPuma J . Episodic oral antibiotic use in CF: Discordance between the electronic medical record and self-report. J Cyst Fibros. 2016; 15(5):630-3. PMC: 5014681. DOI: 10.1016/j.jcf.2016.04.009. View

Carmody L, Kalikin L, VanDevanter D, Li G, Opron K, Simon R . Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis. J Cyst Fibros. 2022; 21(5):766-768. PMC: 10440828. DOI: 10.1016/j.jcf.2022.05.011. View

10.

Caverly L, Lu J, Carmody L, Kalikin L, Shedden K, Opron K . Measures of Cystic Fibrosis Airway Microbiota during Periods of Clinical Stability. Ann Am Thorac Soc. 2019; 16(12):1534-1542. PMC: 6956830. DOI: 10.1513/AnnalsATS.201903-270OC. View

11.

Kerem E, Viviani L, Zolin A, Macneill S, Hatziagorou E, Ellemunter H . Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. Eur Respir J. 2013; 43(1):125-33. DOI: 10.1183/09031936.00166412. View

12.

Quanjer P, Stanojevic S, Cole T, Baur X, Hall G, Culver B . Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012; 40(6):1324-43. PMC: 3786581. DOI: 10.1183/09031936.00080312. View

13.

Graham B, Steenbruggen I, Miller M, Barjaktarevic I, Cooper B, Hall G . Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019; 200(8):e70-e88. PMC: 6794117. DOI: 10.1164/rccm.201908-1590ST. View

14.

Kerwin E, Hickey L, Small C . Relationship between handheld and clinic-based spirometry measurements in asthma patients receiving beclomethasone. Respir Med. 2019; 151:35-42. DOI: 10.1016/j.rmed.2019.03.010. View

15.

Noth I, Cottin V, Chaudhuri N, Corte T, Johannson K, Wijsenbeek M . Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. Eur Respir J. 2021; 58(1). PMC: 8264778. DOI: 10.1183/13993003.01518-2020. View

16.

Bell J, Sivam S, Dentice R, Dwyer T, Jo H, Lau E . Quality of home spirometry performance amongst adults with cystic fibrosis. J Cyst Fibros. 2021; 21(1):84-87. DOI: 10.1016/j.jcf.2021.10.012. View

17.

Zhao J, Schloss P, Kalikin L, Carmody L, Foster B, Petrosino J . Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A. 2012; 109(15):5809-14. PMC: 3326496. DOI: 10.1073/pnas.1120577109. View

18.

Johannson K, Vittinghoff E, Morisset J, Lee J, Balmes J, Collard H . Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. Eur Respir J. 2017; 50(1). PMC: 6029860. DOI: 10.1183/13993003.02406-2016. View

19.

Jenkins B, Glenn L . Variability of FEV1 and criterion for acute pulmonary exacerbation. Front Pediatr. 2014; 2:114. PMC: 4201084. DOI: 10.3389/fped.2014.00114. View

20.

Timmins S, Coatsworth N, Palnitkar G, Thamrin C, Farrow C, Schoeffel R . Day-to-day variability of oscillatory impedance and spirometry in asthma and COPD. Respir Physiol Neurobiol. 2012; 185(2):416-24. DOI: 10.1016/j.resp.2012.08.017. View